Using oral Rifampin to treat acute central serous Chorioretinopathy: a randomized placebo-controlled clinical trial

This study investigated the possible therapeutic effects of oral rifampin on patients with acute Central Serous Chorioretinopathy (CSC). This clinical trial was a randomized placebo-controlled, double-masked research involving 30 patients with acute CSC. The patients were randomly assigned into two groups, one receiving 600 mg of oral rifampin once a day for a month and another being the matched placebo group. The Best Corrected Visual Acuity (BCVA), the subretinal fluid height at the posterior